T-DXd for advanced HER2-positive solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a HER2-positive solid tumor (IHC 3+) that cannot be removed by surgery or has spread to other parts of your body
- You have already received treatment for advanced or metastatic cancer and there are no other good options for you
- Your doctor has decided that T-DXd (Enhertu) is the right treatment for you per FDA guidelines
- You have not had T-DXd before
- You had a scan or test to measure your tumor before starting T-DXd
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
Hear when a new Anal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.